An in-depth look at why Southern California faces an outsized diabetic foot ulcer burden, how regional climate and demographics drive risk, and what comprehensive limb preservation looks like in 2024.
Healix360 supports access to advanced mobile wound care services. Care is coordinated and provided directly by licensed physicians and nurse practitioners experienced in the evaluation and management of chronic and complex wounds, including diabetic foot ulcers, pressure injuries, post-surgical dehiscence, arterial ulcers, venous stasis ulcers, and non-healing traumatic wounds. Across the nine Southern California counties served—Los Angeles, Orange, Riverside, San Bernardino, Ventura, Santa Barbara, Kern, San Luis Obispo, and San Diego—patients are evaluated and treated in private homes, assisted living communities, board-and-care residences, group homes, and skilled nursing facilities.
A diabetic foot ulcer (DFU) is defined as a full-thickness wound below the ankle in a person with diabetes mellitus, typically the result of repetitive pressure on insensate tissue. The central question this article answers is: why is Southern California a particular hotspot for DFUs, and what does effective regional limb preservation actually look like? The short answer is that the combination of high diabetes prevalence (the California Department of Public Health reports diabetes affects roughly 9% of California adults, with several inland Southern California counties exceeding 11%), warm year-round climate that encourages exposed footwear, dense urban geography that complicates clinic access, and significant socioeconomic disparities produces an environment in which DFUs develop earlier, progress faster, and recur more often than national averages.
Diabetes is the leading cause of non-traumatic lower-extremity amputation in the United States. The CDC estimates that roughly 15% of people with diabetes will develop a foot ulcer in their lifetime and that, of those, approximately 14% to 24% will eventually undergo amputation. The American Diabetes Association reports that DFUs precede more than 80% of diabetes-related amputations. In Southern California, where Los Angeles County alone is home to roughly 10 million residents and where Hispanic and Latino populations—who experience disproportionately high rates of type 2 diabetes—make up nearly half of the population in many service areas, the absolute number of patients at risk is staggering.
Inland Empire counties (San Bernardino and Riverside) consistently report some of the highest age-adjusted diabetes mortality rates in the state. In Kern County, agricultural communities face additional barriers including long distances to specialists and seasonal occupational exposures that increase foot trauma. Ventura, Santa Barbara, and San Luis Obispo present a different challenge: aging coastal populations with high vascular disease prevalence and far fewer wound specialists per capita than the major urban cores.
Three pathologic processes converge to produce the diabetic foot ulcer: peripheral neuropathy, peripheral arterial disease (PAD), and immunologic dysfunction. Sensory neuropathy eliminates the protective pain response, allowing repetitive pressure or a stepped-on object to cause tissue injury without the patient noticing. Motor neuropathy weakens the intrinsic muscles of the foot, producing a characteristic claw-toe deformity that increases plantar pressure on the metatarsal heads. Autonomic neuropathy reduces sweating and produces dry, fissured skin that loses its mechanical and microbial barrier function.
Layered on top of these neuropathic changes, PAD compromises macrovascular and microvascular perfusion to the foot. Hyperglycemia impairs neutrophil function, dulls the inflammatory response, and produces advanced glycation end products that stiffen collagen and reduce tissue resilience. The end result is a wound that, once opened, lacks the perfusion, sensory feedback, and immune competence necessary to close on its own. Without specialist intervention, a 'simple' callus blister can become osteomyelitis within weeks.
A diabetic foot ulcer that has not shown measurable progress within four weeks of evidence-based standard care is considered chronic and significantly elevates the risk of infection, hospitalization, and amputation. Specialist referral should not be delayed past this window.
Southern California's mild climate is widely considered one of its greatest assets, but it has a downside for patients with diabetes. Open-toed sandals, slip-on slides, and unstructured footwear are worn nearly year-round. For a patient with intact protective sensation, this is harmless. For a patient with peripheral neuropathy, an unprotected toe is a foreign-body injury waiting to happen. Beach sand, pool decks, and patio surfaces in cities like Long Beach, Santa Monica, Newport Beach, and San Diego routinely reach surface temperatures above 130°F in summer, capable of producing full-thickness thermal burns that the patient does not feel.
Climate also drives chronic mild dehydration in older adults across the region, particularly in the inland deserts of Riverside and San Bernardino counties and in the southern San Joaquin Valley extension into Kern County. Dehydration reduces tissue perfusion exactly where granulation tissue is trying to form. Education about hydration, appropriate footwear, and daily foot self-inspection is therefore not optional—it is core to every wound care visit.
Effective management starts with a structured evaluation. The licensed physicians and nurse practitioners coordinated through Healix360 follow a standardized workup at the bedside that mirrors the recommendations of the International Working Group on the Diabetic Foot (IWGDF) and the Wound Healing Society.
The Wound Healing Society defines the standard of care for a diabetic foot ulcer as the simultaneous application of three pillars: aggressive debridement of devitalized tissue, mechanical offloading of pressure from the wound site, and treatment of any active infection. Failure to address even one of these pillars predicts non-healing.
When a properly debrided, properly offloaded ulcer fails to demonstrate at least 50% area reduction at four weeks, advanced therapies become indicated. The licensed physicians and nurse practitioners coordinated through Healix360 routinely use the following modalities at the bedside, often without the need for a hospital outpatient visit.
Multiple randomized trials published in the Journal of Wound Care, Wound Repair and Regeneration, and JAMA have demonstrated that incorporating cellular and tissue-based products into standard care can increase 12-week closure rates of diabetic foot ulcers by 40% to 60% compared with standard care alone.
Diabetic foot infections range from superficial cellulitis to limb-threatening necrotizing fasciitis. The Infectious Diseases Society of America (IDSA) classification is used at the bedside to determine severity. Mild infections involving only skin and subcutaneous tissue can often be managed with oral antibiotics directed at gram-positive organisms. Moderate to severe infections, particularly those associated with systemic signs or with bone involvement, require coordination with the patient's primary care physician or hospitalist for appropriate imaging (plain films, MRI when indicated) and often hospitalization for IV antibiotics and surgical debridement.
Probe-to-bone testing performed at the bedside has a high positive predictive value for osteomyelitis when the wound is deep and exposed bone is palpable through the wound bed. Suspected osteomyelitis is escalated promptly to limit the risk of disease progression and amputation.
No diabetic foot ulcer should be assumed to have adequate perfusion. Approximately half of patients with DFUs have concurrent peripheral arterial disease, and many of those would benefit from endovascular or surgical revascularization. The bedside ABI is a reasonable first screen, but it is unreliable in the presence of medial arterial calcinosis, which is common in long-standing diabetes. Toe-brachial index, transcutaneous oxygen measurement (TcPO2), and pulse-volume recordings (PVR) are more reliable in this population.
Healix360-coordinated visits include a vascular screen at every encounter and trigger prompt referral to vascular surgery partners across the region—commonly Cedars-Sinai, Keck Medicine of USC, UCLA Health, Kaiser Permanente, and Providence in Los Angeles County, with parallel referral networks in Orange, Riverside, San Bernardino, San Diego, and the Central Coast counties.
"Limb preservation is a team sport. The wound specialist, vascular surgeon, infectious disease physician, and primary care doctor each play a defined role, and the patient does best when those roles are coordinated rather than sequential." — Healix360 Clinical Team
Diabetic foot ulcers are uniquely well suited to the mobile care model. The single most important behavioral intervention—offloading—is almost completely undermined by the very act of traveling to a clinic. Every step a patient takes on a plantar ulcer to get from the parking lot to the clinic door delays healing. Bringing the clinician to the patient eliminates this paradox and makes consistent offloading achievable.
DFUs recur in roughly 40% of patients within one year of closure and 60% within three years according to longitudinal data summarized by the American Diabetes Association. Prevention is therefore a permanent program rather than a one-time intervention. The Healix360 model includes structured post-closure follow-up that focuses on protective footwear, skin care, glucose control coordination with the primary physician, and prompt recognition of any new lesion.
Healix360-coordinated visits integrate with the major Southern California health systems that already manage many of these patients. In Los Angeles County, frequent collaboration occurs with Cedars-Sinai, Keck Medicine of USC, UCLA Health, Kaiser Permanente, and Providence. In Orange County, collaboration extends to Hoag, MemorialCare, and Providence St. Joseph. The Inland Empire is served in coordination with Loma Linda University Health, Kaiser Permanente, and Riverside University Health System. San Diego patients are coordinated with UC San Diego Health, Sharp HealthCare, and Scripps. This is not a parallel system—it is a complement to the patient's existing care team, designed to ensure that wound care does not slip through the cracks between specialty appointments.
If you, a family member, or a patient under your care has a diabetic foot ulcer that is not healing, the path forward is straightforward. Call 877-545-1300 to reach the Healix360 intake team. Provide basic demographic and insurance information. The team will verify benefits and schedule an initial bedside evaluation, typically within 24 to 48 hours. From the first visit, a clear plan is in place and the patient's primary care physician is kept informed at every step.
Healix360-coordinated mobile wound care for diabetic foot ulcers is available across nine Southern California counties—Los Angeles, Orange, Riverside, San Bernardino, Ventura, Santa Barbara, Kern, San Luis Obispo, and San Diego—plus the Las Vegas metro area (Clark and Nye counties in Nevada).
Early signs include redness or warmth over a pressure point, a small blood blister or callus that has developed unusual color, drainage on the inside of socks or shoes, an unusual odor, or a small break in the skin that does not seem to be healing. Because diabetic neuropathy can mute pain, the absence of discomfort is not reassuring. Any new lesion below the ankle in a person with diabetes warrants prompt evaluation.
The 30-day rule from the Wound Healing Society is a useful benchmark: a diabetic foot wound that has not demonstrated measurable improvement within four weeks of conservative care is considered chronic and significantly elevates the risk of infection and amputation. In practice, given how quickly DFUs can progress, it is reasonable to involve a wound specialist within the first one to two weeks rather than waiting.
Yes. Bedside sharp debridement, advanced biologic skin substitute application (EpiFix, AmnioBand, Apligraf, Dermagraft), negative pressure wound therapy initiation and management, and antimicrobial dressing selection are all routinely performed in the home. Wounds that require hospital admission—such as those with limb-threatening infection, exposed deep structures, or required revascularization—are escalated promptly to the appropriate hospital partner.
Offloading means redistributing weight away from the ulcerated area so it has the mechanical opportunity to heal. Without offloading, no dressing, biologic, or antibiotic will close a plantar ulcer because every step reinjures the wound bed. Total contact casting, removable cast walkers made irremovable, felted foam pads, and custom diabetic footwear are all used depending on the location and severity of the ulcer.
Year-round warm weather encourages open-toed and unstructured footwear, which dramatically raises the risk of unnoticed puncture wounds and thermal burns in patients with neuropathy. Pavement, pool decks, and beach sand can exceed 130°F in summer. Inland counties also see significant dehydration in older adults, which reduces tissue perfusion and slows healing. Footwear and hydration counseling are a routine part of every visit.
Yes, when applied to a qualifying chronic wound that has failed at least four weeks of standard care. Medicare Part B covers the application as a medically necessary service. Healix360's intake team verifies coverage before the first application and, when a Medicare Advantage plan requires prior authorization, handles that process administratively so the visit can proceed without delay.
Hyperglycemia impairs neutrophil function, slows collagen synthesis, and produces advanced glycation end products that stiffen tissue. Patients with HbA1c above 8.5% to 9% generally heal more slowly and have higher infection rates. The wound specialist coordinates with the primary care physician or endocrinologist to optimize glycemic control as part of the overall plan, recognizing that aggressive lowering during an acute infection has its own risks and must be individualized.
Initial visits are typically weekly, with the frequency adjusted based on wound trajectory, the need for biologic graft applications (often weekly or every other week), and acute changes such as new infection. A patient who is healing predictably may transition to every-other-week or monthly visits, and a patient whose wound is deteriorating may be seen more frequently.
Plantar ulcers require the most aggressive offloading because every step reinjures the wound. Total contact casting is the gold standard for many of these wounds and can be applied at the bedside in many cases. When TCC is not appropriate, a removable cast walker rendered irremovable with adhesive tape provides a strong second-line option. Felted foam offloading pads are used for forefoot and digital ulcers.
Suspicion is raised when probe-to-bone testing is positive—when a sterile probe inserted gently into the wound contacts bone. This finding has a high positive predictive value in the diabetic foot. Confirmation typically requires plain films and, when indicated, MRI, which is coordinated with the patient's primary care physician or hospitalist. Confirmed osteomyelitis is escalated promptly to ensure timely IV antibiotic therapy and any needed surgical management.
Yes, with a structured prevention program. This includes custom diabetic footwear with multi-density inserts, daily home foot inspection, skin moisturization, routine podiatric nail and callus care, glycemic control coordination, and smoking cessation when applicable. Recurrence rates are high but markedly reduced when a comprehensive prevention plan is followed long-term.
No. Healix360-coordinated mobile wound care complements the existing care team. The wound specialist communicates regularly with the patient's podiatrist, vascular surgeon, primary care physician, and any other specialists, ensuring that everyone is working from the same plan. The goal is to fill the in-between care gap that often determines whether a wound closes or progresses to amputation.
Call 877-545-1300 or request a provider to begin care. Healix360 serves Southern California and Nevada and accepts Medicare Part B and most major insurance plans.